Entos Pharmaceuticals Inc.

Canada

Retour au propriétaire

1-34 de 34 pour Entos Pharmaceuticals Inc. Trier par
Recheche Texte
Affiner par
Type PI
        Brevet 17
        Marque 17
Juridiction
        États-Unis 19
        International 7
        Canada 5
        Europe 3
Date
2025 (AACJ) 1
2024 5
2023 8
2022 11
2021 3
Voir plus
Classe IPC
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases 6
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens 6
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides 5
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice 5
A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester 4
Voir plus
Classe NICE
42 - Services scientifiques, technologiques et industriels, recherche et conception 14
05 - Produits pharmaceutiques, vétérinaires et hygièniques 13
40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau 10
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture. 10
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture 8
Voir plus
Statut
En Instance 15
Enregistré / En vigueur 19

1.

SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Numéro d'application 18713809
Statut En instance
Date de dépôt 2022-11-29
Date de la première publication 2025-03-20
Propriétaire ENTOS PHARMACEUTICALS, INC. (Canada)
Inventeur(s)
  • Jiang, Hong
  • Lewis, John
  • Raturi, Arun
  • Thompson, Thornton

Abrégé

The present disclosure relates to vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use. The vaccine formulations further comprise DNA vectors encoding SARS-Cov-2 spike protein variants comprising single amino acid substitutions and polynucleotides which encode an adjuvant, further wherein the vaccine is formulated with a proteolipid vesicle or fusogenic membrane protein.

Classes IPC  ?

  • A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
  • A61P 31/14 - Antiviraux pour le traitement des virus ARN
  • C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
  • C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

2.

SARS COV-2 VACCINES, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Numéro d'application 18678619
Statut En instance
Date de dépôt 2024-05-30
Date de la première publication 2024-12-05
Propriétaire
  • Aegis Life, Inc. (USA)
  • Entos Pharmaceuticals, Inc. (Canada)
Inventeur(s)
  • Lewis, John
  • Raturi, Arun
  • Duncan, Roy
  • Wee, Ping
  • Bhandari, Prakash
  • Thompson, Thornton
  • Sevy, Alex

Abrégé

The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

Classes IPC  ?

  • A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
  • A61K 9/50 - Microcapsules
  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
  • A61P 37/04 - Immunostimulants

3.

SARS COV-2 VACCINES, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Numéro d'application US2024031700
Numéro de publication 2024/249651
Statut Délivré - en vigueur
Date de dépôt 2024-05-30
Date de publication 2024-12-05
Propriétaire
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventeur(s)
  • Lewis, John
  • Raturi, Arun
  • Duncan, Roy
  • Wee, Ping
  • Bhandari, Prakash
  • Thompson, Thornton
  • Sevy, Alex

Abrégé

The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

Classes IPC  ?

  • A61K 39/12 - Antigènes viraux
  • C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus

4.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Numéro d'application 18613605
Statut En instance
Date de dépôt 2024-03-22
Date de la première publication 2024-11-14
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Lewis, John David
  • Raturi, Arun

Abrégé

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

Classes IPC  ?

  • A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
  • A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
  • A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
  • A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
  • A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

5.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Numéro d'application 18029823
Statut En instance
Date de dépôt 2021-10-01
Date de la première publication 2024-06-13
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Lewis, John David
  • Raturi, Arun

Abrégé

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

Classes IPC  ?

  • A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
  • A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
  • A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
  • A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
  • A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique

6.

DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT

      
Numéro d'application 18303407
Statut En instance
Date de dépôt 2023-04-19
Date de la première publication 2024-03-21
Propriétaire
  • Aegis Life, Inc. (USA)
  • Entos Pharmaceuticals, Inc. (Canada)
Inventeur(s)
  • Sevy, Alexander
  • Abel, Brian
  • Jiang, Hong
  • Raturi, Arun
  • Thompson, Thornton
  • Lewis, John
  • Wee, Ping

Abrégé

The present disclosure relates to systems for the expression of antibodies or antigen binding fragments in a subject, as well as methods of treatments of diseases therewith.

Classes IPC  ?

  • C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
  • A61P 35/00 - Agents anticancéreux

7.

DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT

      
Numéro d'application US2023019104
Numéro de publication 2023/205239
Statut Délivré - en vigueur
Date de dépôt 2023-04-19
Date de publication 2023-10-26
Propriétaire
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventeur(s)
  • Sevy, Alexander
  • Abel, Brian
  • Jiang, Hong
  • Raturi, Arun
  • Thompson, Thornton
  • Lewis, John
  • Wee, Ping

Abrégé

The present disclosure relates to systems for the expression of antibodies or antigen binding fragments in a subject, as well as methods of treatments of diseases therewith.

Classes IPC  ?

  • A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
  • A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
  • C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
  • A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
  • C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
  • C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
  • A61P 35/00 - Agents anticancéreux
  • A61P 31/12 - Antiviraux

8.

Recombinant polypeptides for membrane fusion and uses thereof

      
Numéro d'application 17933193
Numéro de brevet 12454557
Statut Délivré - en vigueur
Date de dépôt 2022-09-19
Date de la première publication 2023-06-22
Date d'octroi 2025-10-28
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Duncan, Roy
  • Clancy, Eileen Kathryn
  • Lewis, John
  • De Antueno, Roberto Justo
  • Nesbitt, Rae-Lynn

Abrégé

Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.

Classes IPC  ?

  • C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
  • A61K 9/1271 - Liposomes non conventionnels, p. ex. liposomes modifiés par un PEG ou liposomes enduits de ou greffés avec des polymères
  • C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
  • C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées

9.

SARS COV-2 VACCINE, ASSOCIATED POLYNUCLEOTIDES, AND METHODS OF USE

      
Numéro d'application US2022051178
Numéro de publication 2023/097102
Statut Délivré - en vigueur
Date de dépôt 2022-11-29
Date de publication 2023-06-01
Propriétaire
  • AEGIS LIFE, INC. (USA)
  • ENTOS PHARMACEUTICALS, INC. (Canada)
Inventeur(s)
  • Jiang, Hong
  • Lewis, John
  • Raturi, Arun
  • Thompson, Thornton

Abrégé

The present disclosure relates to vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use. The vaccine formulations further comprise DNA vectors encoding SARS-Cov-2 spike protein variants comprising single amino acid substitutions and polynucleotides which encode an adjuvant, further wherein the vaccine is formulated with a proteolipid vesicle or fusogenic membrane protein.

Classes IPC  ?

  • A61K 39/12 - Antigènes viraux
  • A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
  • A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
  • A61P 31/14 - Antiviraux pour le traitement des virus ARN
  • C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
  • C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation

10.

PLV

      
Numéro d'application 018875766
Statut Enregistrée
Date de dépôt 2023-05-16
Date d'enregistrement 2023-10-04
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock); Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases; pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers); vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis); pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery agents that facilitate the intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents. Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies. Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates. Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes.

11.

FUSOGENIX

      
Numéro d'application 018875828
Statut Enregistrée
Date de dépôt 2023-05-16
Date d'enregistrement 2023-10-04
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock); Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases; pharmaceutical and medicinal preparations and substances, all for the treatment of chronic diseases, namely, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers); vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis); pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery agents that facilitate the intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents. Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies. Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates. Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes.

12.

PLV

      
Numéro de série 97939663
Statut En instance
Date de dépôt 2023-05-16
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the nature of pneumonia, kidneys in the nature of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery system, comprising FAST proteins for intracellular delivery of therapeutic agents; drug delivery system, comprising naturally occurring, engineered and FAST proteins fused to antibodies, polypeptide sequences and targeting ligands, namely, Alpha-V/Beta3, RGD, EGFL7, PC3, Hepsin, Protease cleaved collagen IV and Plectin, for intracellular delivery of therapeutic agents; drug delivery system, comprising charged, ionizable and cationic lipids to neutralize nucleic acid cargo(es) and overall particle charge for intracellular delivery of therapeutic agents; drug delivery system, comprising helper lipids to mediate particle morphology, structure, fluidity and FAST protein stabilization for intracellular delivery of therapeutic agents; drug delivery system, comprising conjugated lipids, namely, pegylated lipids for stability and size, and cargoes, namely, DNA, plasmid DNA, circular DNA, single stranded DNA, RNA, mRNA, siRNA, miRNA, shRNA, tRNA, protein, peptides, small molecules, and combinations thereof for intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes

13.

FUSOGENIX

      
Numéro de série 97939674
Statut En instance
Date de dépôt 2023-05-16
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the nature of pneumonia, kidneys in the nature of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; Drug delivery system, comprising FAST proteins for intracellular delivery of therapeutic agents; drug delivery system, comprising naturally occurring, engineered and FAST proteins fused to antibodies, polypeptide sequences and targeting ligands, namely, Alpha-V/Beta3, RGD, EGFL7, PC3, Hepsin, Protease cleaved collagen IV and Plectin, for intracellular delivery of therapeutic agents; drug delivery system, comprising charged, ionizable and cationic lipids to neutralize nucleic acid cargo(es) and overall particle charge for intracellular delivery of therapeutic agents; drug delivery system, comprising helper lipids to mediate particle morphology, structure, fluidity and FAST protein stabilization for intracellular delivery of therapeutic agents; drug delivery system, comprising conjugated lipids, namely, pegylated lipids for stability and size, and cargoes, namely, DNA, plasmid DNA, circular DNA, single stranded DNA, RNA, mRNA, siRNA, miRNA, shRNA, tRNA, protein, peptides, small molecules, and combinations thereof for intracellular delivery of therapeutic agents; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals and therapeutic agents Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes

14.

COMPOSITIONS AND METHODS FOR LIVER-SPECIFIC EXPRESSION OF FOLLISTATIN

      
Numéro d'application US2022045468
Numéro de publication 2023/056070
Statut Délivré - en vigueur
Date de dépôt 2022-09-30
Date de publication 2023-04-06
Propriétaire
  • OISIN BIOTECHNOLOGIES, INC. (USA)
  • ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Scholz, Matthew Rein
  • Lewis, John David

Abrégé

Provided herein are expression constructs for liver-specific expression of transgenes, such as follistatin. Also provided are delivery vectors for the expression constructs, and methods of expressing follistatin in a subject to increase muscular strength and mass, or treat a condition.

Classes IPC  ?

  • C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
  • A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
  • C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
  • A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
  • C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques

15.

PLV

      
Numéro d'application 222386200
Statut En instance
Date de dépôt 2022-11-23
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

16.

FUSOGENIX

      
Numéro d'application 222386100
Statut En instance
Date de dépôt 2022-11-23
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

17.

ENTOS

      
Numéro de série 97978410
Statut Enregistrée
Date de dépôt 2022-09-14
Date d'enregistrement 2024-11-19
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely gene therapy services; medical analysis services, namely RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purpose

18.

ENTOS

      
Numéro de série 97980623
Statut En instance
Date de dépôt 2022-09-14
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ? 05 - Produits pharmaceutiques, vétérinaires et hygièniques

Produits et services

Pharmaceutical and medicinal preparations and substances, namely, human vaccines; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic eye diseases, chronic muscle diseases, and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; therapeutic and preventative cancer vaccines for human use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, inflammatory muscle diseases and disorders, diabetes, obesity, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, muscular dystrophy, genetic diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, respiratory diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare respiratory, pulmonary and lung diseases, rare liver diseases, rare eye diseases, rare muscle diseases

19.

ENTOS

      
Numéro de série 97590573
Statut En instance
Date de dépôt 2022-09-14
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux

Produits et services

Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems, namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic bone diseases; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely, Crohn's and ulcerative colitis, fatty liver disease, endometriosis, arthritis, autoimmune diseases and disorders, hypoglycemia, gout, osteoarthritis, anemia, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare inflammatory diseases, rare cardiovascular diseases, rare kidney diseases, rare bone diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry Nucleic acid sequencers for scientific purposes Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

20.

ENTOS

      
Numéro de série 97590585
Statut En instance
Date de dépôt 2022-09-14
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux

Produits et services

Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for laboratory use for use in the biotechnological industry; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems namely, the lung in the name of pneumonia, kidneys in the name of pyelonephritis, gastrointestinal track in the nature of gastritis, enteritis, colitis, systemic blood infections in the nature of sepsis/septic shock, skin infections in the nature of cellulitis, central nervous system in the nature of meningitis, encephalitis, walled off infections in the nature of abscesses, liver in the nature of hepatitis, head and neck infections in the nature of conjunctivitis, uveitis, sinusitis; chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers in the nature of hematological cancers and solid organ cancers; vaccines that are viral, bacterial, fungal for human use; vaccines that are viral, bacterial, fungal for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis which is viral, alcoholic, autoimmune, inflammatory bowel disease, namely Crohn's and ulcerative colitis, fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely, Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely, dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely, rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases; cell culture media for cultivating human, animal, plant or microorganism cells for use in the biotechnological industry Nucleic acid sequencers for scientific purposes Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection

21.

ENTOS

      
Numéro de série 97977591
Statut Enregistrée
Date de dépôt 2022-09-14
Date d'enregistrement 2024-07-16
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

Custom manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticals, therapeutic agents and medical devices; research and product development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates Medical therapy services, namely, gene therapy services; medical analysis services, namely, RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; genetic testing for medical purposes

22.

ENTOS

      
Numéro d'application 220893000
Statut En instance
Date de dépôt 2022-09-09
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for use in the biotechnological industry; (2) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (3) Nucleic acid sequencers for scientific purposes; (4) Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection; (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

23.

ENTOS

      
Numéro d'application 220893100
Statut En instance
Date de dépôt 2022-09-09
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 09 - Appareils et instruments scientifiques et électriques
  • 10 - Appareils et instruments médicaux
  • 40 - Traitement de matériaux; recyclage, purification de l'air et traitement de l'eau
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception
  • 44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.

Produits et services

(1) Reagents for scientific purposes for use in nucleic acid isolation and purification; cell culture media for use in the biotechnological industry; (2) Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, namely, viral infections, bacterial infections, fungal infections, parasitic infections and prion diseases, infections of multiple organ systems such as but not limited to the lung (pneumonia), kidneys (pyelonephritis), gastrointestinal track (gastritis, enteritis, colitis), systemic blood infections (sepsis/septic shock), skin infections (cellulitis), central nervous system (meningitis, encephalitis), walled off infections (abscesses), liver (hepatitis), head and neck infections (conjunctivitis, uveitis, sinusitis, etc); chronic diseases, namely, chronic neurological and nervous system diseases and other mental illnesses, chronic respiratory, pulmonary and lung diseases, chronic inflammatory diseases, chronic cardiovascular diseases, chronic liver diseases, chronic kidney diseases, chronic bone diseases, chronic eye diseases, chronic oral diseases, chronic blood diseases, chronic spleen diseases, chronic pancreatic diseases, chronic thyroid diseases, chronic reproductive disease, chronic gastrointestinal diseases, chronic skin diseases, chronic muscle diseases, chronic bone diseases and cancers (hematological cancers and solid organ cancers; vaccines (viral, bacterial, fungal, etc) for human use; vaccines (viral, bacterial, fungal, etc) for veterinary use; therapeutic and preventative cancer vaccines for human use; therapeutic and preventative cancer vaccines for veterinary use; diagnostic preparations for medical purposes for detecting genetic predispositions; diagnostic reagents for clinical laboratory use; diagnostic preparations for clinical laboratory use; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the diagnosis, treatment and prevention of a variety of diseases and disorders, namely, cancer, inflammatory diseases and disorders, namely, inflammatory bowel diseases and disorders, inflammatory connective tissue diseases and disorders, inflammatory pelvic diseases and disorders, inflammatory muscle diseases and disorders, asthma, coeliac disease, hepatitis (viral, alcoholic, autoimmune, etc.), inflammatory bowel disease (Crohn's and ulcerative colitis), fatty liver disease, diabetes, endometriosis, arthritis, obesity, autoimmune diseases and disorders, metabolic diseases and disorders, namely, metabolic enzyme deficiencies, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, genetic diseases and disorders, infectious diseases, namely, blood infections, respiratory infections, topical infections, cardiovascular diseases and disorders, neurological diseases and disorders, namely Alzheimer's, Huntington's Disease, cerebral palsy, brain injury, spinal cord injury and seizure disorders, hematological diseases and disorders, dermatological diseases and disorders, namely dermatitis, skin pigmentation diseases, psoriasis, eczema, acne, shingles, hives, rosacea, ophthalmological diseases and disorders, gastrointestinal diseases and disorders, genitourinary diseases and disorders, namely, urological diseases and disorders, infertility, sexually transmitted diseases, acute renal failure, benign ptostatic hyperplasia, endometrial ablation, renal diseases and disorders, respiratory diseases and disorders, connective tissues diseases and disorders, and enzyme deficiency diseases and disorders, rare and orphan diseases, and rare genetic diseases and disorders, namely rare neurological and nervous system diseases and other mental illnesses, rare respiratory, pulmonary and lung diseases, rare inflammatory diseases, rare cardiovascular diseases, rare liver diseases, rare kidney diseases, rare bone diseases, rare eye diseases, rare oral diseases, rare blood diseases, rare spleen diseases, rare pancreatic diseases, rare thyroid diseases, rare reproductive disease, rare gastrointestinal diseases, rare skin diseases, rare muscle diseases, rare bone diseases (3) Nucleic acid sequencers for scientific purposes; (4) Medical devices for the qualitative detection and testing of DNA and RNA in human specimens for the detection of influenza viruses and nucleic acid detection; (1) Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; (2) Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; genetic testing for medical purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific research, pharmaceutical research, medical research, technical consultation and product development for others in the field of biotechnology and development of pharmaceuticals, therapeutic agents and medical devices; research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; (3) Gene therapy services; RNA or DNA analysis for virus diagnosis and prognosis; medical information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; on-line information services, namely, providing information to physicians, healthcare professionals and patients on the topics of health issues that can be treated with vaccines, recombinant proteins and antibodies, diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies;

24.

Methods for diagnosing and treating metastatic cancer

      
Numéro d'application 17558705
Numéro de brevet 12421514
Statut Délivré - en vigueur
Date de dépôt 2021-12-22
Date de la première publication 2022-04-14
Date d'octroi 2025-09-23
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abrégé

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

Classes IPC  ?

  • C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
  • A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
  • A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
  • A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
  • A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
  • A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
  • A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
  • C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
  • C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

25.

PROTEOLIPID VESICLES FORMULATED WITH FUSION ASSOCIATED SMALL TRANSMEMBRANE PROTEINS

      
Numéro d'application CA2021051377
Numéro de publication 2022/067446
Statut Délivré - en vigueur
Date de dépôt 2021-10-01
Date de publication 2022-04-07
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Lewis, John David
  • Raturi, Arun

Abrégé

Disclosed is a proteolipid vesicle (PLV) for delivering a therapeutic cargo, such as nucleic acids, polypeptides and molecules, to a cell, the proteolipid vesicle having a lipid nanoparticle comprising one or more ionizable lipids and one or more of a fusion associated small transmembrane (FAST) family of proteins and chimerics thereof, where the molar ratio of ionizable lipid to therapeutic cargo is between 2.5:1 and 20:1. Incorporation of a chimeric FAST protein into a PLV platform enhances intracellular delivery and expression of mRNA and pDNA both in vitro and in vivo. These PLVs also display a favorable immune profile and are significantly less toxic than conventional LNPs.

Classes IPC  ?

  • A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
  • A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
  • A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
  • A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
  • A61K 9/51 - Nanocapsules
  • A61P 35/00 - Agents anticancéreux
  • A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
  • B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
  • C07C 217/28 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un groupe amino et au moins deux atomes d'oxygène liés par des liaisons simples, dont au moins un fait partie d'un groupe hydroxy éthérifié, liés au squelette carboné, p. ex. éthers de polyhydroxyamines
  • C07C 219/08 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé au moins un des groupes hydroxy étant estérifié par un acide carboxylique ayant le groupe carboxyle estérifiant lié à un atome de carbone acyclique d'un squelette carboné acyclique non saturé
  • C07C 69/025 - Esters d'acides acycliques monocarboxyliques saturés dont le groupe carboxyle est lié à un atome de carbone acyclique ou à l'hydrogène estérifiés par des alcools non saturés dont le groupe hydroxyle estérifié est lié à un atome de carbone acyclique
  • C07F 9/10 - Phosphatides, p. ex. lécithine
  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
  • C07K 17/02 - Peptides immobilisés sur, ou dans, un support organique
  • C07K 19/00 - Peptides hybrides
  • C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
  • C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
  • C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation

26.

ENTOS

      
Numéro d'application 018605861
Statut Enregistrée
Date de dépôt 2021-11-22
Date d'enregistrement 2022-05-18
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 09 - Appareils et instruments scientifiques et électriques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

chemical and biological agents for scientific and research use. pharmaceuticals; pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; chemical preparations and biological preparations for the treatment of diseases and disorders; veterinary preparations, namely veterinary drugs. Downloadable computer software; downloadable software applications; downloadable software for optimizing the development and discovering of new and existing molecules, drugs, and batteries, all for use in the field of computer science, chemistry, biochemistry, physics, chemical engineering, and biology; downloadable software applications for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products; customized downloadable computer software using artificial intelligence and machine learning to provide bespoke digital simulations in the fields of chemistry, physics, biology, biochemistry, computer science, and chemical engineering. Providing temporary use of non-downloadable software; software as a service [SaaS]; platform as a service [PaaS]; research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (saas) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (paas) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products.

27.

ENTOS

      
Numéro d'application 214212000
Statut En instance
Date de dépôt 2021-10-21
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Classes de Nice  ?
  • 01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
  • 05 - Produits pharmaceutiques, vétérinaires et hygièniques
  • 09 - Appareils et instruments scientifiques et électriques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

(1) Chemical and biological agents for scientific and research use (2) Pharmaceuticals; pharmaceutical preparations for treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders and therapeutic agents for the treatment of autoimmune diseases, cancer, cardiovascular diseases and disorders, endocrine diseases and disorders, gastrointestinal diseases and disorders, infectious diseases, psychiatric and psychological diseases and disorders, neurological diseases and disorders, rare diseases, and respiratory diseases and disorders; chemical preparations and biological preparations for the treatment of diseases and disorders; veterinary preparations (3) Downloadable software for optimizing the development and discovering of new and existing molecules, drugs, and batteries, all for use in the field of computer science, chemistry, biochemistry, physics, chemical engineering, and biology; downloadable software applications for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products; customized downloadable computer software using artificial intelligence and machine learning to provide bespoke digital simulations in the fields of chemistry, physics, biology, biochemistry, computer science, and chemical engineering (1) Research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (saas) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (paas) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

28.

ENTOS

      
Numéro de série 90894329
Statut Enregistrée
Date de dépôt 2021-08-20
Date d'enregistrement 2023-08-29
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Classes de Nice  ? 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (saas) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (paas) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

29.

ENTOS

      
Numéro de série 88930350
Statut Enregistrée
Date de dépôt 2020-05-22
Date d'enregistrement 2021-07-13
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Classes de Nice  ?
  • 09 - Appareils et instruments scientifiques et électriques
  • 42 - Services scientifiques, technologiques et industriels, recherche et conception

Produits et services

Downloadable software for optimizing the development and discovering of new and existing molecules, drugs, and batteries, all for use in the field of computer science, chemistry, biochemistry, physics, chemical engineering, and biology; downloadable software applications for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products; customized downloadable computer software using artificial intelligence and machine learning to provide bespoke digital simulations in the fields of chemistry, physics, biology, biochemistry, computer science, and chemical engineering Scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

30.

Recombinant oncolytic viruses for treatment of metastatic cancers

      
Numéro d'application 16626019
Numéro de brevet 12378289
Statut Délivré - en vigueur
Date de dépôt 2018-06-22
Date de la première publication 2020-04-23
Date d'octroi 2025-08-05
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Duncan, Roy
  • Pan, Chungen

Abrégé

Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.

Classes IPC  ?

  • C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
  • A61K 35/765 - RéovirusRotavirus
  • A61K 35/766 - Rhabdovirus, p. ex. virus de la stomatite vésiculaire
  • A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
  • C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

31.

Methods for diagnosing and treating metastatic cancer

      
Numéro d'application 16309800
Numéro de brevet 11236331
Statut Délivré - en vigueur
Date de dépôt 2017-06-14
Date de la première publication 2019-06-13
Date d'octroi 2022-02-01
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abrégé

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, Cl4orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

Classes IPC  ?

  • C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
  • A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
  • A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
  • A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
  • A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
  • A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
  • A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
  • C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
  • C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs

32.

RECOMBINANT ONCOLYTIC VIRUSES FOR TREATMENT OF METASTATIC CANCERS

      
Numéro d'application CA2018050766
Numéro de publication 2018/232523
Statut Délivré - en vigueur
Date de dépôt 2018-06-22
Date de publication 2018-12-27
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Duncan, Roy
  • Pan, Chungen

Abrégé

Disclosed are recombinant oncolytic viruses that express one or more reovirus fusion-associated small transmembrane (FAST) proteins and uses thereof. The oncolytic activity of the recombinant oncolytic viruses expressing FAST proteins can be used to treat primary and metastatic cancers, especially from breast and colon cancers.

Classes IPC  ?

  • C12N 7/01 - Virus, p. ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
  • A61K 35/76 - VirusParticules sous-viralesBactériophages
  • A61K 35/766 - Rhabdovirus, p. ex. virus de la stomatite vésiculaire
  • A61P 35/00 - Agents anticancéreux
  • A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
  • C07K 14/14 - Réoviridae, p. ex. rotavirus, virus de la langue bleue du mouton, virus de la fièvre à tiques du Colorado
  • C12N 15/46 - Réoviridae, p. ex. rotavirus, virus de la langue bleue du mouton, virus de la fièvre à tiques du Colorado
  • C12N 15/86 - Vecteurs viraux

33.

METHODS FOR DIAGNOSING AND TREATING METASTATIC CANCER

      
Numéro d'application CA2017050729
Numéro de publication 2017/214726
Statut Délivré - en vigueur
Date de dépôt 2017-06-14
Date de publication 2017-12-21
Propriétaire ENTOS PHARMACEUTICALS INC. (Canada)
Inventeur(s)
  • Lewis, John
  • Stoletov, Konstantin
  • Willetts, Lian

Abrégé

Disclosed are methods of diagnosing and treating metastatic cancer in a subject. The methods involve detecting or modulating the expression of at least one of Kif3b, ACTB, SRPK1, TM EM 229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, miRNA 130b, miRNA 374b, or miRNA 122 in a biological sample from the subject.

Classes IPC  ?

  • A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
  • A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
  • A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
  • A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
  • A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
  • C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
  • C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
  • G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
  • G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

34.

Recombinant polypeptides for membrane fusion and uses thereof

      
Numéro d'application 13877101
Numéro de brevet 10227386
Statut Délivré - en vigueur
Date de dépôt 2011-09-29
Date de la première publication 2014-10-23
Date d'octroi 2019-03-12
Propriétaire Entos Pharmaceuticals Inc. (Canada)
Inventeur(s)
  • Duncan, Roy
  • Clancy, Eileen Kathryn
  • Lewis, John
  • De Antueno, Roberto Justo
  • Nesbitt, Rae-Lynn

Abrégé

Disclosed is a recombinant polypeptide for facilitating membrane fusion. The recombinant polypeptide having a sequence with at least 80% sequence identity with the ectodomain of p14 fusion-associated small transmembrane (FAST) protein and having a functional myristoylation motif, a transmembrane domain from a FAST protein and a sequence with at least 80% sequence identity with the endodomain of p15 FAST protein. A targeting ligand can be added to the recombinant polypeptide for selective fusion. The recombinant polypeptide can be included in the membrane of a liposome, or the like, to facilitate the delivery of bioactive compounds, such as siRNA, or the recombinant polypeptide can be mixed with a lipid carrier and added to cultured cells to induce cell-cell fusion and heterokaryon formation.

Classes IPC  ?

  • C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
  • C07K 14/01 - Virus à ADN
  • A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
  • C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
  • C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées